Durvalumab after definitive chemoradiotherapy in locally advanced NSCLC: Data of the German EAP

Martin Faehling; Christian Schumann; Petros Christopoulos; Petra Hoffknecht; Jürgen Alt; Marlitt Horn; Stephan Eisenmann; Anke Schlenska-Lange; Philipp Schütt; Felix Steger; Wolfgang M Brückl; Daniel C Christoph

doi:10.1016/j.dib.2020.106556

Durvalumab after definitive chemoradiotherapy in locally advanced NSCLC: Data of the German EAP

Data Brief. 2020 Dec 5:34:106556. doi: 10.1016/j.dib.2020.106556. eCollection 2021 Feb.

Authors

Affiliations

¹ Klinik für Kardiologie und Pneumologie, Klinikum Esslingen, 73730 Esslingen, Germany.
² Klinik für Pneumologie, Thoraxonkologie, Schlaf- und Beatmungsmedizin, Klinikum Kempten, 87439 Kempten, Germany.
³ Thoraxklinik-Heidelberg, 69126 Heidelberg, Germany.
⁴ Klinik für Thoraxonkologie und Palliativstation, Franziskus-Hospital Harderberg, 49124 Georgsmarienhütte, Germany.
⁵ III. Medizinische Klinik und Poliklinik, Johannes Gutenberg-Universität, 55131 Mainz, Germany.
⁶ LungenClinic Grosshansdorf, Großhansdorf, Germany.
⁷ Universitätsklinik und Poliklinik für Innere Medizin I (Gastroenterologie & Pneumologie), Universitätsklinikum Halle (Saale), 06120 Halle, Germany.
⁸ Klinik für Onkologie und Hämatologie, Krankenhaus Barmherzige Brüder Regensburg, 93049 Regensburg, Germany.
⁹ Onkologische Gemeinschaftspraxis, Gütersloh, Germany.
¹⁰ Klinik und Poliklinik für Strahlentherapie, Universitätsklinikum Regensburg, 93053 Regensburg, Germany.
¹¹ Klinik für Innere Medizin 3, Klinikum Nürnberg Nord, 90419 Nürnberg, Germany.
¹² Klinik für Internistische Onkologie und Hämatologie mit integrierter Palliativmedizin, Evang. Kliniken Essen-Mitte, 45136 Essen, Germany.

Abstract

Following the PACIFIC trial, durvalumab has been approved by the European Medicines Agency (EMA) for consolidation of locally advanced PD-L1-positive NSCLC after chemoradiotherapy (CRT). Patients were treated with durvalumab in the EAP from 22.11.2017 to 15.10.2018 allowing analysis of its efficacy and safety. 211 patients were registered by 90 German centres. Data were collected retrospectively by questionnaire and queries. 56 centres reported data on 126 patients who actually received at least one cycle of durvalumab. In contrast to the PACIFIC-trial population, some patients with oligometastatic disease and a history of autoimmune disease are included in the EAP population. Information on PD-L1 status was obtained for 111 patients. Baseline data include age, gender, ECOG, stage (IASLC 8th ed.), and smoking history. Treatment data include mode of chemoradiotherapy, used chemotherapy agent, and duration of durvalumab therapy. Adverse evants were documented according to CTAEC 5.0. Data were analysed for progression-free survival (PFS), overall survival (OS), and adverse events (AE). The results were published in Lung Cancer [1].

Keywords: Autoimmune; Checkpoint inhibitor; NSCLC; Oligometastatic; PD-L1; Real world; Survival.